2021-01-27 15:05:36 GMT2021-01-27 23:05:36(Beijing Time) Xinhua English
NAIROBI, Jan. 27 (Xinhua) British pharmaceutical firm GlaxoSmithKline (GSK) on Wednesday signed a product transfer agreement for malaria vaccine with Bharat Biotech (BBIL) of India to boost its access in Africa.
The agreement will facilitate seamless transfer of manufacturing of the protein part of the malaria vaccine from GSK to BBIL and boost action on the leading killer of African children and pregnant mothers. With a child dying from malaria every two minutes, helping secure the long-term future of the only vaccine available by working with an established leader like Bharat Biotech is vital for the continued fight against the devastating disease, Thomas Breuer, chief medical officer of GSK vaccines said in a statement issued in Nairobi.
Bharat Biotech to make malaria vaccine
Updated:
Updated:
Firm inks product transfer pact with GSK, PATH
Share Article
Firm inks product transfer pact with GSK, PATH
Global pharma major GSK, non-profit health organisation PATH and Bharat Biotech have signed a product transfer agreement pertaining to malaria vaccine RTS,S/AS01.
The agreement includes transfer of manufacturing of the RTS,S antigen part of the vaccine and grant of a licence on all rights pertaining to the RTS,S/AS01 malaria vaccine to Bharat Biotech.
A joint release on Wednesday said GSK will retain production of the adjuvant of the vaccine (AS01E) and supply the same to Bharat Biotech.
Business EconomyPosted at: Jan 27 2021 9:52PM
GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine
Kolkata, Jan 27 (UNI) GSK, PATH, and Bharat Biotech (BBIL) today announced the signing of a product transfer agreement for the malaria vaccine, RTS,S/AS01E 1 . The agreement includes the transfer of manufacturing of the RTS,S antigen part of the vaccine and the grant of a license on all rights pertaining to the RTS,S/AS01 malaria vaccine to BBIL. GSK will retain the production of the adjuvant of the vaccine (AS01E) and will supply it to BBIL.
Bharat Biotech enters pact with GSK, PATH to produce, distribute malaria vaccine
As per the agreement GSK will transfer the manufacturing technology of the RTS,S antigens of the vaccine and will grant license on all rights pertaining to the RTS,S/AS01 malaria vaccine to Bharat Biotech. GSK will retain the production of the adjuvant of the vaccine (AS01E) and will supply it to Bharat Biotech. January 27, 2021 / 06:28 PM IST
Bharat Biotech, UK drug giant GSK and US-based non-profit PATH on January 27 announced the signing of a product transfer agreement for the malaria vaccine.
As per the agreement, GSK will transfer the manufacturing technology of the RTS,S antigens of the vaccine and will grant license on all rights pertaining to the RTS,S/AS01 malaria vaccine to Bharat Biotech. GSK will retain the production of the adjuvant of the vaccine (AS01E) and supply it to Bharat Biotech.
Bharat Biotech to make antigen for first-ever anti-malaria vaccine
By IANS |
Published on
Wed, Jan 27 2021 18:42 IST |
0 Views
Over 60 envoys visit Bharat Biotech facility in Hyderabad. Image Source: IANS News
Hyderbad, Jan 27 : Global healthcare company GSK, non-profit agency working to end health inequity PATH, and vaccine maker Bharat Biotech on Wednesday announced the signing of a product transfer agreement for malaria vaccine RTS,S/AS01E1.
The agreement includes the transfer of manufacturing of the RTS,S antigen part of the vaccine and the grant of a license on all rights pertaining to the RTS,S/AS01 malaria vaccine to Hyderabad-based Bharat Biotech International Ltd (BBIL). GSK will retain the production of the adjuvant of the vaccine (AS01E) and will supply it to Bharat Biotech.